The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

NCT00266799 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pegylated liposomal doxorubicin (SCH 200746)
DRUG: Capecitabine

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]